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Abstract 
Background: Critically appraising the quality of clinical practice guidelines (CPGs) is an essential element of evi-
dence implementation. Critical appraisal considers the quality of CPG construction and reporting processes, and the 
credibility of the body of evidence underpinning recommendations. To date, the focus on CPG critical appraisal has 
come from researchers and evaluators, using complex appraisal instruments. Rapid critical appraisal is a relatively new 
approach for CPGs, which targets busy end-users such as service managers and clinicians. This paper compares the 
findings of two critical appraisal instruments: a rapid instrument (iCAHE) and a complex instrument (AGREE II). They 
were applied independently to 16 purposively-sampled, heterogeneous South African CPGs, written for eleven pri-
mary health care conditions/health areas. Overall scores, and scores in the two instruments’ common domains Scope 
and Purpose, Stakeholder involvement, Underlying evidence/Rigour of Development, Clarity), were compared using 
Pearson r correlations and intraclass correlation coefficients. CPGs with differences of 10 % or greater between scores 
were identified and reasons sought for such differences. The time taken to apply the instruments was recorded.
Results: Both instruments identified the generally poor quality of the included CPGs, particularly in Rigour of Devel-
opment. Correlation and agreement between instrument scores was moderate, and there were no overall significant 
score differences. Large differences in scores for some CPGs could be explained by differences in instrument con-
struction and focus, and CPG construction. The iCAHE instrument was demonstrably quicker to use than the AGREE II 
instrument.
Conclusions: Either instrument could be used with confidence to assess the quality of CPGs. The choice of appraisal 
instrument depends on the needs and time of end-users. Having an alternative (rapid) critical appraisal tool will 
potentially encourage busy end-users to identify and use good quality CPGs to inform practice decisions.
Keywords: Clinical practice guidelines (CPGs), Rapid appraisal tool, iCAHE checklist, AGREE II, Complex appraisal tool, 
CPG quality, Reporting standards, Primary health care, South Africa
© 2016 Grimmer et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Over 20  years ago, Woolf [1–3] described clinical prac-
tice guidelines (CPGs) as ‘the new reality for medicine’. 
Research continues into how best to present this ‘new 
reality’ to end users in a way that will improve evidence 
uptake. Whilst there is no one internationally-agreed 
standard for developing CPGs [4–6], there is a general 
expectation that CPG recommendations should be trans-
parently based on current best evidence [7–11].
End-users of CPGs are those who put CPG recom-
mendations into operation, such as service managers 
and healthcare workers ‘at the coal face’. These people 
are rarely engaged in CPG writing [12], however they 
are usually well aware of the barriers to evidence-uptake 
[13–16]. These are consistently reported as lack of time, 
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money, and knowledge [3, 13–16]. Thus when end-users 
choose a CPG, they need to be assured that it is of the 
best possible quality, and that it will efficiently assist 
them to provide quality care. Service managers and clini-
cians are busy people, and therefore to assist them in effi-
ciently identifying and using quality CPGs, they require 
a time-efficient critical appraisal instrument that is com-
prehensive, simple, robust and efficient.
An Australian team at the International Centre for 
Allied Health Evidence (iCAHE), University of South 
Australia, developed and tested a 14 question binary-
scored (yes  =  1, no  =  0) CPG appraisal instrument, 
designed specifically for busy end-users [17]. The iCAHE 
instrument was developed in partnership with service 
managers, policy-makers and clinicians, and incorpo-
rated their perceptions of important elements of CPG 
quality relevant to their settings. The iCAHE instrument 
contains 14 questions and provides one overall score 
(total out of 14). This scoring approach assumes equal 
weighting for each question, reflecting the views held by 
the end-users who assisted in its development.
The psychometric properties of the iCAHE instru-
ment were established by comparison with AGREE II 
(Appraisal of Guideline Research and Evaluation), a 
complex CPG critical appraisal instrument [7, 18–20]. 
AGREE II is well-known internationally, and is recom-
mended for assessing CPG quality by the South Afri-
can Medical Journal [8, 9]. AGREE II has 23 statements 
grouped into six domains of Scope and Purpose; Stake-
holder Involvement; Rigour of Development; Clarity 
of Presentation; Applicability; and Editorial Independ-
ence. Each statement is scored using a 1–7 scale, with 1 
being no agreement and 7 being total agreement. The six 
domains in AGREE II are intended to be reported sepa-
rately, and the scoring rubric is not designed to provide 
an overall quality score [18, 19].
The iCAHE and AGREE II instruments share four 
domains (Scope and Purpose, Stakeholder involve-
ment, Underlying evidence/Rigour, Clarity). The iCAHE 
instrument also includes three domains not in AGREE 
II (currency, a summary of findings, and availabil-
ity), whilst AGREE II includes two domains not in the 
iCAHE instrument (Applicability, and Independence) 
(see Table  1). The scores and utility of the iCAHE and 
AGREE II instruments were compared using six CPGs 
for mild traumatic brain injury [17]. Overall, the iCAHE 
and AGREE II scores correlated moderately well (Pearson 
r = 89 %). Depending on the complexity of CPG layout, 
the iCAHE instrument took between 5 and 10 min per-
CPG to apply, whilst the AGREE II instrument scoring 
per-CPG per-tester took up to an hour.
The South African Guidelines Excellence (SAGE) is 
a project which aims to improve the quality of South 
African primary health care (PHC) CPGs. It is pursuing 
several research activities, namely identifying, and speak-
ing with, key individuals and groups involved in PHC 
CPG writing and use in South Africa; determining the 
quality of current South African PHC CPGs and identi-
fying ways to improve their quality; and building capac-
ity in best practice CPG writing, implementation and 
evaluation in South African academics, clinicians and 
policy-makers [21]. The SAGE team recently reported 
on the quality of 16 purposively-sampled South African 
CPGs for priority PHC conditions, using AGREE II [22]. 
These CPGs comprised the most recent versions of seven 
disease-specific and four integrated multi-disease South 
African PHC CPGs (see Table 2, reproduced from Mach-
ingaidze et al. [22]). The dates of CPG publication ranged 
from 2002 to 2014. Overall, the quality domains of Rig-
our of Development, and Editorial Independence had the 
poorest scores, whilst Scope and Purpose, and Clarity of 
Presentation generally scored the best. The time taken to 
score each selected CPGs with AGREE II ranged between 
45 and 60  min, depending on CPG layout, comprehen-
siveness and complexity.
AGREE II was developed for, and has been largely used 
by, researchers and CPG developers, thus its use may 
present challenges for time-constrained end-users who 
have to assess CPG quality by themselves. The iCAHE 
instrument could be a viable alternative to AGREE II 
when a rapid overview of CPG quality is required. This 
paper describes how the iCAHE instrument compares to 
the AGREE II instrument on a larger set of heterogene-
ous CPGs.
Methods
Data set
The same 16 purposively-selected South African PHC 
CPGs reported by Machingaidze et al. [22] were assessed 
using the iCAHE instrument, and the scores from the 
two instruments were compared.
Scoring
The iCAHE instrument was applied by one independent 
experienced tester whose level of experience was similar 
to that of the testers who applied the AGREE II instru-
ment [22].
Data management
To facilitate comparison between instrument scores for 
each CPG, a percent of possible total (overall) score was 
calculated for the iCAHE instrument and also from the 
AGREE II instrument. This approach was previously used 
when initially validating the iCAHE instrument against 
AGREE II [17], even though a total AGREE II score is not 
calculated from the AGREE II domain rubric [18, 19]. 
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Table 1 iCAHE questions mapped against AGREE II domains and their statements
Adapted from Grimmer et al. [17]
iCAHE AGREE II
AGREE II domain 1: scope 
and purpose
Q13 Are the purpose and target users of the guideline 
stated?
Q1. The overall objectives of the guideline are specifically 
described
Q2. The health questions covered by the guideline are specifi-
cally described
Q3. The population to whom the guideline is meant to apply 
is specifically described
AGREE II domain 2: stake-
holder involvement
Q6. The target users are clearly defined
Q11. Are the developers clearly stated? Q4. The guideline development group includes individuals 
from all relevant professional groups
Q12. Does the qualifications and expertise of the guide-
line developers link with the purpose of the guideline 
and its end users?
Q5. The views and preferences of the target population have 
been sought
AGREE II domain 3: rigour 
of development
Q7. Does the guideline provide an outline of the strategy 
used to find underlying evidence?
Q7. Systematic methods were used to search for the evidence
Q8. Does the guideline use a hierarchy to rank the quality 
of the underlying evidence?
Q8. The criteria for selecting the evidence are clearly described
Q9. Does the guideline appraise the quality of the evi-
dence which underpins its recommendations?
Q9. The strengths and limitations of the body of evidence are 
clearly described
Q10. Does the guideline link the hierarchy and quality of 
underlying evidence to each recommendation?
Q10. The methods for formulating the recommendations are 
clearly described
Q11. The health benefits, side effects and risks have been 
considered in formulating the recommendations
Q12. There is an explicit link between the recommendations 
and the supporting evidence
Q13. The guideline has been eternally reviewed by experts 
prior to its publication
Q14. A procedure for updating the guideline is provided
iCAHE instrument domain: 
currency
Q4. Is there a date of completion available?
Q5. Does the guideline provide an anticipated review 
date?
Q6. Does the guideline provide dates for when literature 
was included?
AGREE II domain 4: clarity 
of presentation
Q14. Is the guideline readable and easy to navigate? Q15. The recommendations are specific and unambiguous
Q16. The different options for management of the condition 
or health issues are clearly presented
Q17. Key recommendations are easily identifiable
AGREE II domain 5: appli-
cability
Q18. The guideline describes facilitators and barriers to its 
application
Q19. The guideline provides advice and/or tools on how the 
recommendations can be put into practice
Q20. The potential resources implications of applying the 
recommendations have been considered
Q21. The guideline presents monitoring and/or auditing 
criteria
AGREE II domain 6: edito-
rial independence
Q22. The views of the funding body have not influenced the 
content of the guideline
Q23. Competing interests of guideline development group 
members have been recorded and addressed
iCAHE instrument domain: 
availability
Q1. Is the guideline readily available in full text?
Q2. Does the guideline provide a complete reference list?
iCAHE instrument domain: 
summary
Q3. Does the guideline provide a summary of its recom-
mendations?
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To calculate one percent total score, the individual item 
responses for all AGREE II statements were applied to 
the scoring rubric, using a minimum possible score of 23 
(calculated as 23 items*1), and a maximum possible score 
of 171, calculated as 23 items*7. This score was then 
reported as a percentage of the possible total.
Analysis
Correlation between instrument scores was reported as 
Pearson correlation coefficients (Pearson r). Significance 
of instrument score differences was determined using p 
values from single factor analysis of variance (ANOVA) 
models, and intraclass correlation coefficients (ICC(2,1)) 
were calculated from the mean square outputs of these 
ANOVA models. The ICC(2,1) calculation assumed that 
the testers were similar to those who might use the 
instruments in other situations. CPGs with instrument 
score differences of  >10  % (where positive differences 
favoured the iCAHE instrument) were identified. The 
two datasets were:
1. The % total iCAHE scores and the % total AGREE II 
scores for each CPG, using all items in each instru-
ment (23 AGREE II statements, 14 iCAHE ques-
tions).
2. The % total scores for only the items in the instru-
ments’ common domains (Scope and Purpose, Stake-
holder involvement, Rigour of development, Clarity 
of Presentation). This involved eight iCAHE ques-
tions and 17 AGREE II statements. The same pro-
cess of calculating total AGREE II scores was used as 
described in the Data management paragraph, how-
ever the denominators were 8 (8*1) for iCAHE and 
119 (17 items*7) for AGREE II.
The time spent critically appraising the iCAHE instru-
ment was recorded for each CPG, and compared with the 
time reported by Machingaidze et al. [22].
Results
Overall CPG quality
Irrespective of whether the iCAHE or AGREE II instru-
ment was used, or the number of questions/statements 
compared, the overall quality of reporting in the South 
African PC CPGs was generally poor (See Table 3; Figs. 1 
and 2).
Table 2 South African CPGs included in this analysis (reproduced from Machingaidze et al. [22])
Name Short name Publication year Developer
Disease specific guidelines
Clinical guidelines for the management of HIV and 
AIDS in adults and adolescents
Adult HIV 2010 National Department of Health
Guidelines for the management of HIV in children Child HIV 2010 National Department of Health
Clinical guidelines: PMTCT (prevention of mother-to-
child transmission)
PMTCT 2010 National Department of Health
National tuberculosis management guidelines Adult TB 2014 National Department of Health
Guidelines for the management of tuberculosis in 
children
Child TB 2013 National Department of Health
Malaria prevention guidelines Malaria prevention 2011 National Department of Health
Malaria treatment guidelines Malaria treatment 2010 National Department of Health
Combination guidelines
Standard treatment guidelines and essential medicines 
list for South Africa
EDL 2008 National Department of Health
Integrated management of childhood illnesses IMCI 2002 National Department of Health
Guidelines for maternity care in South Africa Maternal 2007 National Department of Health
Primary care 101 PC101 2013 UCT Lung Institute/National Department of Health
Guidelines by professional societies
Guideline for the management of acute asthma in 
adults: 2013 update
Adult asthma 2013 South African Thoracic Society
Guideline for the management of acute asthma in 
children: 2013 update
Child asthma 2013 South African Thoracic Society
Guideline for the management of chronic obstructive 
pulmonary disease—2011 update
COPD 2011 South African Thoracic Society
South African hypertension guideline 2011 Hypertension 2011 Southern African Hypertension Society
The 2012 SEMDSA guideline for the management of 
type 2 diabetes (Revised)
Type II diabetes 2012 Society for endocrinology, metabolism and diabetes 
of South Africa
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Table  4 reports the findings from analyses 1 and 2. 
Comparing analysis 1 with 2, there was an improved 
correlation between instrument scores for analysis 2, as 
well as a stronger ICC(2,1) score (with a lower, but not 
significant, p value). There were no significant percent-
age of score differences overall, from either analysis 1 or 
2. However from analysis 1, the large score differences all 
favoured the iCAHE instrument (see Fig. 1), whilst from 
analysis 2, the large score differences mostly favoured the 
AGREE II instrument (see Fig. 2).
The time to use the iCAHE instrument was 3–5  min 
per CPG. This mirrored earlier findings on the utility of 
the iCAHE instrument [17].
Discussion
This study compare findings from a complex CPG critical 
appraisal instrument (AGREE II) with a rapid appraisal 
instrument (iCAHE), on a sizeable sample of heteroge-
neous country-specific PHC CPGs. Scoring CPG qual-
ity is an essential element of evidence implementation 
[10, 11, 13–16]. Unless end-users have confidence in the 
quality of the evidence underpinning CPG recommenda-
tions, they are unlikely to adopt them. CPGs offer ready 
access to a ‘one-stop-shop’ for current best evidence-
summaries [1–3]. Irrespective of which critical appraisal 
instrument was used (rapid or complex), we identified 
consistent concerns relating to the quality of the selected 
South African PHC CPGs, particularly in Rigour of 
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
iCAHE
AGREE II
Fig. 1 Analysis 1 findings: comparison of % of total scores per CPG, 
including all questions (iCAHE instrument) and statements (AGREE II)
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0 iCAHE %
AGREE %
Fig. 2 Analysis 2 findings: comparison of % of total scores per CPG 
for the common domains only
Table 4 Pearson r correlation coefficients, ICC(2,1) values for  agreement and  CPGs with  disagreements  >10  %, listed 
by order of size of disagreement for analyses 1 and 2
Pearson r  
correlation  
coefficient
Agreement  
expressed as  
ICC(2,1) values
CPGs with  
disagreements > 10 %  
between instruments
Size of disagreement 
(-ve values in favour 
of AGREE II) (%)
Analysis 1: using all statements in 
both instruments
0.39 ICC = 0.06 (p = 0.39) (6 of 16)
Child asthma 34.8 
Adult asthma 23.3 
Malaria treatment 22.7 
Malaria prevention 18.9 
COPD 17.4 
Hypertension 17.1 
Analysis 2: using only the state-
ments in the common domains 
between the instruments
0.61 ICC = 0.49 (p = 0.07) (7 of 16)
Child asthma 17.1 
Adult asthma 10.9 
Adult HIV −14.5
Child HIV −15.3
PMTCT −15.3
PC101 −24.7
Adult TB −29.0
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Development. This is a similar finding to other studies 
evaluating South African CPG quality [8, 9].
Analysis 1, which compared the per-CPG total scores 
derived from the 23 AGREE statements, and the 14 
iCAHE questions, demonstrated the modesty of both 
correlation and agreement. This was attributed to the 
variability in number and intent, in the two instruments’ 
items. For instance, whilst there were four common 
domains between instruments, the iCAHE questions 
included additional domains of Currency, Availability, 
and Summary, whilst the AGREE II instrument included 
additional domains of Applicability and Editorial Inde-
pendence. Comparing differences in total scores, all six 
CPGs with large percent differences (>10 %) favoured the 
iCAHE instrument.
Analysis 2, which compared data from just the four 
shared domains in the iCAHE and AGREE II instru-
ments, showed improved correlation and agreement, 
but identified different CPGs with large score differences 
(with only two of the seven highlighted CPGs favouring 
the iCAHE instrument). This suggests that the between-
instrument differences in the number of statements/
questions in the common domains possibly influenced 
the scoring (8 iCAHE questions in four domains, 17 
AGREE II statements in the same four domains). This 
potentially weighted the overall score in favour of AGREE 
II.
The shorter time taken to score CPG quality using 
iCAHE instrument compared with AGREE II reflects 
the smaller number of items, as well as the utility of the 
binary-scored iCAHE instrument, where no subjectiv-
ity in interpretation is required. In comparison, Mach-
ingaidze et  al. [22] reported that the AGREE II scores 
took as much as 10 times longer to compile per CPG, 
as its use required personal judgement identify a score 
from 1 to 7 for each statement, and then the application 
of a scoring rubric per domain. As previously reported 
[17], this potentially introduces uncertainty in critical 
appraisal.
Conclusions
Both appraisal instruments provide standard valid and 
reliable frameworks for assessment of CPG quality, albeit 
oriented for different end users. Thus either instrument 
could be used with confidence to assess the quality of a 
CPG, and the choice of instrument would depend on the 
purpose of appraisal, available time and whether addi-
tional personnel were available to apply the AGREE II 
scoring requirements. Having an alternative (rapid) criti-
cal appraisal tool will potentially encourage busy end-
users who may not currently use complex tools such as 
AGREE II, to identify good quality CPGs to inform prac-
tice and policy decisions.
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